indazoles has been researched along with gdc-0973 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belvin, M; Berry, L; Choo, EF; Lewin-Koh, N; Merchant, M; Ng, CM; Salphati, L | 1 |
| Bakalarski, CE; Belvin, M; Bustos, DJ; Chan, J; Dogan, T; Friedman, LS; Hoeflich, KP; Kirkpatrick, DS; Phu, L; Song, Q; Young, A | 1 |
| Bou-Reslan, H; Cao, T; Carano, R; Castillo, J; Chan, E; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, W; French, D; Hoeflich, KP; Junttila, MR; Merchant, M; Metcalfe, C; Nannini, MA; Otter, DD; Singh, M | 1 |
| Bustos, D; Kirkpatrick, DS; Phu, L; Varfolomeev, E; Vucic, D; Yu, K | 1 |
| Barr, M; Cuffe, S; Finn, S; Gately, K; Heavey, S; Leonard, N; McVeigh, N; Nicholson, S; O'Byrne, K; Ryan, R; Young, V | 1 |
| Buclin, T; Cagnon, L; Cardoso, E; Csajka, C; Decosterd, L; Diezi, M; Ellefsen-Lavoie, K; Homicsko, K; Mercier, T; Michielin, O; Wagner, AD; Widmer, N | 1 |
| Bendell, J; Chan, IT; Cleary, JM; de Crespigny, A; Fredrickson, J; Gates, MR; Hsieh, HJ; Jones, S; Kurkjian, C; Kwak, E; LoRusso, P; Musib, L; Pandya, S; Pilat, MJ; Rudin, CM; Shapiro, GI; Wongchenko, M; Yan, Y | 1 |
| Fan, Q; Li, Q; Liu, F; Ma, J; Zhang, B; Zhao, B | 1 |
1 trial(s) available for indazoles and gdc-0973
| Article | Year |
|---|---|
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Class I Phosphatidylinositol 3-Kinases; Female; GTP Phosphohydrolases; Humans; Indazoles; Male; Membrane Proteins; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sulfonamides; Treatment Outcome; Young Adult | 2020 |
7 other study(ies) available for indazoles and gdc-0973
| Article | Year |
|---|---|
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Female; Indazoles; MAP Kinase Kinase 1; Melanoma; Mice; Mice, Nude; Models, Biological; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition.
Topics: Azetidines; Blotting, Western; Cell Line, Tumor; Chromatography, Liquid; DNA Damage; Humans; Indazoles; Linear Models; Melanoma; Mitogen-Activated Protein Kinase Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Piperidines; Proteomics; Signal Transduction; Sulfonamides; Tandem Mass Spectrometry | 2013 |
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Indazoles; MAP Kinase Kinase 1; Mice; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Standard of Care; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Immunoaffinity enrichment coupled to quantitative mass spectrometry reveals ubiquitin-mediated signaling events.
Topics: Apoptosis; Azetidines; Cell Line, Tumor; DNA Damage; Enzyme Inhibitors; Humans; Indazoles; Interleukin-17; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase Kinases; Mitochondrial Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Proteins; Proteomics; Signal Transduction; Sulfonamides; Tandem Mass Spectrometry; Transcription Factors; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination | 2015 |
In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
Topics: A549 Cells; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azetidines; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Lung Neoplasms; Male; MAP Kinase Kinase Kinases; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2016 |
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Administration, Oral; Antineoplastic Agents; Azetidines; Child; Chromatography, High Pressure Liquid; Humans; Imidazoles; Indazoles; Indoles; Limit of Detection; Linear Models; Oximes; Phenylurea Compounds; Piperidines; Pyridines; Pyridones; Pyrimidines; Pyrimidinones; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry; Vemurafenib | 2018 |
Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Topics: Acute Kidney Injury; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Azetidines; Benzamides; Female; Hospital Mortality; Hospitalization; Humans; Indazoles; Male; Middle Aged; Odds Ratio; Pharmacovigilance; Piperidines; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sirolimus; United States; United States Food and Drug Administration; Young Adult | 2020 |